Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2001-01-11
2004-02-10
Paras, Jr., Peter (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C800S021000, C800S025000, C800S018000, C536S023100, C435S325000
Reexamination Certificate
active
06689937
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to transgenic non-human animal models of basal cell carcinoma. More specifically, the present invention is directed to mouse models of basal cell carcinoma allowing for the characterization of the mechanism of the disease as well as for developing and testing potential treatments.
BACKGROUND OF THE INVENTION
Throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure.
Approximately 1,000,000 epithelial skin cancers are diagnosed in the United States each year
1
, and the great majority of these are basal cell carcinomas (BCCs). The pathogenesis of these tumors involves constitutive activation of the Sonic hedgehog (Shh) signaling pathway
2-4
. In many BCCs this can be attributed to loss-of-function mutations involving PTCH1
5,6
, which encodes a SHH receptor and antagonist. However, the identity of the specific downstream effector in the Shh pathway leading to cancer development remains unknown.
It is now demonstrated that transgenic mice overexpressing the transcription factor Gli2 in cutaneous keratinocytes develop multiple skin tumors that are grossly indistinguishable from human BCCs. These tumors express the same protein markers as human BCCs and exhibit strikingly elevated levels of Ptch1 and Gli1, a hallmark of human BCCs but not squamous tumors. These results establish Gli2 as a potent oncogene in skin and suggest a pivotal role for this transcription factor in the development of BCC, the most common cancer in humans.
With the development of transgenic animal models for basal cell carcinoma potential treatments including effective drug therapies can now be developed and tested.
SUMMARY OF THE INVENTION
The present invention provides transgenic non-human models of basal cell carcinoma and more specifically transgenic mouse models of basal cell carcinoma which allows for the characterization of the disease as well as for providing a system for the development and testing of potential treatments. In particular the invention provides transgenic mice overexpressing the transcription factor Gli2 in cutaneous keratinocytes which leads to the development of multiple skin tumors that are grossly indistinguishable from human BCCs. The present invention also provides methods for the production of non-human transgenic animal models of basal cell carcinoma as well as methods for testing compounds for an effect on basal cell carcinoma. The invention also encompasses isolated cells from the transgenic animal models as well as isolated eggs of the transgenic animals.
In accordance with the present invention there is provided a transgenic non-human animal model for basal cell carcinoma.
In accordance with another aspect of the present invention is a transgenic mouse model for basal cell carcinoma. The basal cell carcinoma as developed by the transgenic models physiologically resembles that of human basal cell carcinoma.
According to an aspect of the invention is a transgenic mouse model characterized by having a great similarity to several physiological conditions existing in naturally occurring human basal cell carcinoma, based on the expression of keratin 17 (K17), Bcl-2, keratin K5 and the non-expression of keratin K1 and keratin K6 as well as on histological analysis. Furthermore, the basal cell carcinoma tumors developed by the transgenic mice also express the same protein markers as human basal cell carcinomas as well as elevated levels of Ptch
1
and Gli1.
According to another aspect of the invention is a transgenic mouse whose genome contains at least one copy of a Gli2 nucleotide sequence wherein said mouse develops basal cell carcinoma. The nucleotide sequence may be genomic DNA, cDNA or RNA.
According to a further aspect of the invention is a transgenic mouse whose somatic and germ cells comprise a Gli2 nucleotide sequence, wherein the expression of said sequence leads to the development of basal cell carcinoma.
In accordance with a first embodiment of the invention, a construct comprising a full-length mouse Gli2 cDNA with an amino-terminal FLAG tag under the control of a bovine keratin 5 (K5) promoter and also containing a rabbit
-globin intron 2 sequence and an SV40 polyA signal was made. The construct was then introduced into mouse embryos using standard techniques such as microinjection. Founders were identified and any skin tumors identified and biologically characterized.
In accordance with a further embodiment of the invention, a binary transgenic system was utilized to target Gli2 overexpression in keratinocytes. In this approach, a Gli2 transgene was placed downstream of a &bgr;geo (lacZ
eomycin) cassette flanked by a pair of loxP sites. Upstream of the &bgr;geo cassette was placed a strong ubiquitous promoter such as the &bgr;actin promoter. This construct was used to create Z/AP-Gli2 mice in which lacZ expression was driven in all cells. In this system, the Gli2 transgene is activated only when the &bgr;geo cassette is excised by Cre recombination. For Gli2 overexpression, the Z/AP-Gli2 mice were crossed with a K5-Cre transgenic line producing K5-Cre:Z/AP-Gli2 mice having a high incidence of basal cell carcinoma. Furthermore, in initial experiments, Cre was electroporated into ES cell clones containing epitope tagged Gli2 or Gli2&Dgr;N and chimeric mice generated by aggregration of ES cells with morula stage mouse embryos. Z/AP-Gli2 and Z/AP- Gli2&Dgr;N mouse lines were established after germline transmission.
Animal cells can be isolated from the transgenic mice or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals or animal cells may then used to screen for compounds altering the pathological course of basal cell carcinoma leading to the development of pharmaceutical therapeutic approaches for treating the disease.
In accordance with a further aspect of the present invention is a transgenic mouse whose somatic and germ cells comprise a nucleic acid construct wherein the construct comprises a nucleic acid encoding Gli2 under the control of a suitable promoter and wherein the construct is transcribed. The construct may additionally contain any suitable polyA elements as well as a suitable regulatory element in order to enhance the expression of the Gli2 transgene.
In one embodiment of the invention the nucleic acid encoding Gli2 is a full length mouse cDNA with an amino-terminal FLAG tag operatively linked to a bovine keratin 5 (K5) promoter. In a further embodiment of the invention such construct further comprises a rabbit
-globin intron
2
sequence and an SV40 polyA signal.
In another embodiment of the invention the nucleic acid encodes amino acids 280-1544 of Gli2 (herein referred to as Gli2&Dgr;N). In a further embodiment, the nucleic acid of the invention encodes Gli2 or a fragment or variant thereof which leads to Gli2 expression.
In accordance with still a further aspect of the present invention is a transgenic mouse whose somatic and germ cells comprise a nucleic acid construct wherein the construct comprises a full-length mouse Gli2 cDNA or variant thereof with an amino-terminal FLAG tag operatively linked to a bovine keratin 5 (K5) promoter and also containing a rabbit
-globin intron 2 sequence and an SV40 polyA signal, and wherein the nucleic acid is expressed in skin cells of the transgenic mouse.
In accordance with another aspect of the present invention is a transgenic mouse whose somatic and germ cells comprise a nucleic acid construct wherein the construct comprises a full-length mouse Gli2 cDNA or variant thereof operatively linked to a &bgr;actin promoter. The Gli2 transgene is activated by Cre recombination leading to expression of the Gli2 nucleic acid sequence in skin cells of the transgenic mouse such
Dlugosz Andrzej A.
Hui Chi-Chung
Myers Bigel Sibley & Sajovec P.A.
Paras, Jr. Peter
The Hospital for Sick Children
LandOfFree
Transgenic mouse model of basal cell carcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic mouse model of basal cell carcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mouse model of basal cell carcinoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3289332